Legislation
- Title
- State Board of Pharmacy - Prohibition on Discrimination Against 340B Drug Distribution
- Sponsored by
- Senator Lam
- Status
- In the House - First Reading House Rules and Executive Nominations
- Analysis
- Fiscal and Policy Note (Revised)
Synopsis
Prohibiting a 340B manufacturer from taking certain direct or indirect actions to limit or restrict the acquisition or delivery of a 340B drug; making a violation of the Act an unfair, abusive, or deceptive trade practice within the meaning of the Consumer Protection Act; and requiring the Maryland Prescription Drug Affordability Board to conduct a study of the 340B Program and report its findings and recommendations to the Senate Finance Committee and the House Health and Government Operations Committee on or before July 1, 2026.
Committees
- Original:
- Finance Click to view Recorded Media
- Opposite:
- Rules and Executive Nominations
Committee Testimony
Details
History
Toggle History Dropdown
File Code
Toggle Filecode Dropdown
Subjects
Toggle Subjects Dropdown
Statutes
Toggle Statutes Dropdown
(
13-301 )
(
12-101, 12-6C-09.1 )
Last Updated: 4/15/2024 3:37 PM